[1]	NUCLEOTIDE SEQUENCE [MRNA]. TISSUE=Ovary; DOI=10.1016/0006-291X(90)91552-4; PubMed=2244890 [NCBI, ExPASy, EBI, Israel, Japan] Minegish T., Nakamura K., Takakura Y., Miyamoto K., Hasegawa Y., Ibuki Y., Igarashi M.; "Cloning and sequencing of human LH/hCG receptor cDNA."; Biochem. Biophys. Res. Commun. 172:1049-1054(1990).
[2]	NUCLEOTIDE SEQUENCE [MRNA]. TISSUE=Ovary; PubMed=1922095 [NCBI, ExPASy, EBI, Israel, Japan] Jia X.-C., Oikawa M., Bo M., Tanaka T., Ny T., Boime I., Hsueh A.J.W.; "Expression of human luteinizing hormone (LH) receptor: interaction with LH and chorionic gonadotropin from human but not equine, rat, and ovine species."; Mol. Endocrinol. 5:759-768(1991).
[3]	NUCLEOTIDE SEQUENCE [MRNA]. TISSUE=Thyroid; PubMed=2293030 [NCBI, ExPASy, EBI, Israel, Japan] Frazier A.L., Robbins L.S., Stork P.J., Sprengel R., Segaloff D.L., Cone R.D.; "Isolation of TSH and LH/CG receptor cDNAs from human thyroid: regulation by tissue specific splicing."; Mol. Endocrinol. 4:1264-1276(1990).
[4]	NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-GLN-18 INS. DOI=10.1016/0303-7207(95)03557-N; PubMed=7556872 [NCBI, ExPASy, EBI, Israel, Japan] Atger M., Misrahi M., Sar S., Leflem L., Dessen P., Milgrom E.; "Structure of the human luteinizing hormone-choriogonadotropin receptor gene: unusual promoter and 5' non-coding regions."; Mol. Cell. Endocrinol. 111:113-123(1995).
[5]	NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-54, AND VARIANT LEU-GLN-18 INS. DOI=10.1159/000022840; PubMed=9858858 [NCBI, ExPASy, EBI, Israel, Japan] Tsai-Morris C.-H., Geng Y., Buczko E., Dehejia A., Dufau M.L.; "Genomic distribution and gonadal mRNA expression of two human luteinizing hormone receptor exon 1 sequences in random populations."; Hum. Hered. 49:48-51(1999).
[6]	3D-STRUCTURE MODELING OF 51-232. DOI=10.1016/S0969-2126(01)00272-6; PubMed=8747461 [NCBI, ExPASy, EBI, Israel, Japan] Jiang X., Dreano M., Buckler D.R., Cheng S., Ythier A., Wu H., Hendrickson W.A., el Tayar N.; "Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone-receptor interactions."; Structure 3:1341-1353(1995).
[7]	PALMITOYLATION AT CYS-643 AND CYS-644, AND MUTAGENESIS OF CYS-643 AND CYS-644. DOI=10.1210/me.2004-0335; PubMed=15539429 [NCBI, ExPASy, EBI, Israel, Japan] Munshi U.M., Clouser C.L., Peegel H., Menon K.M.; "Evidence that palmitoylation of carboxyl terminus cysteine residues of the human luteinizing hormone receptor regulates postendocytic processing."; Mol. Endocrinol. 19:749-758(2005).
[8]	VARIANT FMPP GLY-578. DOI=10.1038/365652a0; PubMed=7692306 [NCBI, ExPASy, EBI, Israel, Japan] Shenker A., Laue L., Kosugi S., Merendino J.J. Jr., Minegishi T., Cutler G.B. Jr.; "A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty."; Nature 365:652-654(1993).
[9]	VARIANTS FMPP ILE-571 AND GLY-578. DOI=10.1093/hmg/2.11.1779; PubMed=8281137 [NCBI, ExPASy, EBI, Israel, Japan] Kremer H., Mariman E., Otten B.J., Moll G.W. Jr., Stoelinga G.B.A., Wit J.M., Jansen M., Drop S.L., Faas B., Ropers H.-H., Brunner H.G.; "Cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty."; Hum. Mol. Genet. 2:1779-1783(1993).
[10]	VARIANT FMPP ILE-577. DOI=10.1093/hmg/4.2.183; PubMed=7757065 [NCBI, ExPASy, EBI, Israel, Japan] Kosugi S., van Dop C., Geffner M.E., Rabl W., Carel J.-C., Chaussain J.-L., Mori T., Merendino J.J. Jr., Shenker A.; "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty."; Hum. Mol. Genet. 4:183-188(1995).
[11]	VARIANT FMPP VAL-572. DOI=10.1210/jc.80.4.1162; PubMed=7714085 [NCBI, ExPASy, EBI, Israel, Japan] Yano K., Saji M., Hidaka A., Moriya N., Okuno A., Kohn L.D., Cutler G.B. Jr.; "A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty."; J. Clin. Endocrinol. Metab. 80:1162-1168(1995).
[12]	VARIANT FMPP VAL-568. DOI=10.1210/jc.80.8.2490; PubMed=7629248 [NCBI, ExPASy, EBI, Israel, Japan] Latronico A.C., Anasti J., Arnhold I.J., Mendonca B.B., Domenice S., Albano M.C., Zachman K., Wajchenberg B.L., Tsigos C.; "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty."; J. Clin. Endocrinol. Metab. 80:2490-2494(1995).
[13]	VARIANT LCH PRO-593. DOI=10.1038/ng0295-160; PubMed=7719343 [NCBI, ExPASy, EBI, Israel, Japan] Kremer H., Kraaij R., Toledo S.P.A., Post M., Fridman J.B., Hayashida C.Y., van Reen M., Milgrom E., Ropers H.-H., Mariman E., Themmen A.P.N., Brunner H.G.; "Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene."; Nat. Genet. 9:160-164(1995).
[14]	VARIANT FMPP ILE-577. DOI=10.1002/(SICI)1098-1004(1996)7:2<164::AID-HUMU13>3.3.CO;2-B; PubMed=8829636 [NCBI, ExPASy, EBI, Israel, Japan] Cocco S., Meloni A., Marini M.G., Cao A., Moi P.; "A missense (T577I) mutation in the luteinizing hormone receptor gene associated with familial male-limited precocious puberty."; Hum. Mutat. 7:164-166(1996).
[15]	VARIANT FMPP THR-398. PubMed=8929952 [NCBI, ExPASy, EBI, Israel, Japan] Evans B.A.J., Bowen D.J., Smith P.J., Clayton P.E., Gregory J.W.; "A new point mutation in the luteinising hormone receptor gene in familial and sporadic male limited precocious puberty: genotype does not always correlate with phenotype."; J. Med. Genet. 33:143-147(1996).
[16]	VARIANT LCH TYR-616. DOI=10.1056/NEJM199602223340805; PubMed=8559204 [NCBI, ExPASy, EBI, Israel, Japan] Latronico A.C., Anasti J., Arnhold I.J.P., Rapaport R., Mendonca B.B., Bloise W., Castro M., Tsigos C., Chrousos G.P.; "Testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene."; N. Engl. J. Med. 334:507-512(1996).
[17]	VARIANT LCH ARG-131. DOI=10.1210/jc.82.7.2159; PubMed=9215288 [NCBI, ExPASy, EBI, Israel, Japan] Misrahi M., Meduri G., Pissard S., Bouvattier C., Beau I., Loosfelt H., Jolivet A., Rappaport R., Milgrom E., Bougneres P.; "Comparison of immunocytochemical and molecular features with the phenotype in a case of incomplete male pseudohermaphroditism associated with a mutation of the luteinizing hormone receptor."; J. Clin. Endocrinol. Metab. 82:2159-2165(1997).
[18]	VARIANTS LEU-GLN-18 INS; SER-284 AND ASN-306. DOI=10.1002/(SICI)1098-1004(1998)11:4<333::AID-HUMU19>3.3.CO;2-4; PubMed=10215412 [NCBI, ExPASy, EBI, Israel, Japan] Wu S.-M., Jose M., Hallermeier K., Rennert O.M., Chan W.-Y.; "Polymorphisms in the coding exons of the human luteinizing hormone receptor gene."; Hum. Mutat. 11:333-334(1998).
[19]	VARIANT FMPP VAL-373. DOI=10.1210/jc.83.2.476; PubMed=9467560 [NCBI, ExPASy, EBI, Israel, Japan] Gromoll J., Partsch C.-J., Simoni M., Nordhoff V., Sippell W.G., Nieschlag E., Saxena B.B.; "A mutation in the first transmembrane domain of the lutropin receptor causes male precocious puberty."; J. Clin. Endocrinol. Metab. 83:476-480(1998).
[20]	VARIANT LCH LYS-354. DOI=10.1210/jc.83.6.2091; PubMed=9626144 [NCBI, ExPASy, EBI, Israel, Japan] Stavrou S.S., Zhu Y.S., Cai L.Q., Katz M.D., Herrera C., Defillo-Ricart M., Imperato-Mcginley J.; "A novel mutation of the human luteinizing hormone receptor in 46XY and 46XX sisters."; J. Clin. Endocrinol. Metab. 83:2091-2098(1998).
[21]	VARIANT FMPP ARG-457. DOI=10.1210/jc.83.7.2435; PubMed=9661624 [NCBI, ExPASy, EBI, Israel, Japan] Latronico A.C., Abell A.N., Arnhold I.J., Liu X., Lins T.S., Brito V.N., Billerbeck A.E., Segaloff D.L., Mendonca B.B.; "A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty."; J. Clin. Endocrinol. Metab. 83:2435-2440(1998).
[22]	VARIANT LEU-GLN-18 INS. DOI=10.1210/jc.83.12.4431; PubMed=9851790 [NCBI, ExPASy, EBI, Israel, Japan] Rodien P., Cetani F., Costagliola S., Tonacchera M., Duprez L., Minegishi T., Govaerts C., Vassart G.; "Evidences for an allelic variant of the human LC/CG receptor rather than a gene duplication: functional comparison of wild-type and variant receptors."; J. Clin. Endocrinol. Metab. 83:4431-4434(1998).
[23]	VARIANT LCH 608-LEU-VAL-609 DEL. DOI=10.1210/me.12.3.442; PubMed=9514160 [NCBI, ExPASy, EBI, Israel, Japan] Latronico A.C., Chai Y., Arnhold I.J.P., Liu X., Mendonca B.B., Segaloff D.L.; "A homozygous microdeletion in helix 7 of the luteinizing hormone receptor associated with familial testicular and ovarian resistance is due to both decreased cell surface expression and impaired effector activation by the cell surface receptor."; Mol. Endocrinol. 12:442-450(1998).
[24]	VARIANT LCH LYS-625. DOI=10.1210/me.12.6.775; PubMed=9626653 [NCBI, ExPASy, EBI, Israel, Japan] Martens J.W., Verhoef-Post M., Abelin N., Ezabella M., Toledo S.P., Brunner H.G., Themmen A.P.; "A homozygous mutation in the luteinizing hormone receptor causes partial Leydig cell hypoplasia: correlation between receptor activity and phenotype."; Mol. Endocrinol. 12:775-784(1998).
[25]	VARIANT LEYDIG CELL TUMOR HIS-578. DOI=10.1056/NEJM199912023412304; PubMed=10580072 [NCBI, ExPASy, EBI, Israel, Japan] Liu G., Duranteau L., Carel J.-C., Monroe J., Doyle D.A., Shenker A.; "Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor."; N. Engl. J. Med. 341:1731-1736(1999).
[26]	VARIANT [LARGE SCALE ANALYSIS] ASN-564. DOI=10.1126/science.1133427; PubMed=16959974 [NCBI, ExPASy, EBI, Israel, Japan] Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E.; "The consensus coding sequences of human breast and colorectal cancers."; Science 314:268-274(2006).

Comments

FUNCTION: Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.
SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
ALTERNATIVE PRODUCTS: 2 named isoforms [FASTA] produced by alternative splicing. Additional isoforms seem to exist.

Name Long

Isoform ID P22888-1

This is the isoform sequence displayed in this entry.

Name Short

Isoform ID P22888-2

Features which should be applied to build the isoform sequence: VSP_001962.
TISSUE SPECIFICITY: Gonadal and thyroid cells.
DISEASE: Defects in LHCGR are a cause of familial male precocious puberty (FMPP) [MIM:176410]; also known as testotoxicosis. In FMPP the receptor is constitutively activated.
DISEASE: Defects in LHCGR are a cause of Leydig cell hypoplasia (LCH) [MIM:152790]. LCH is an autosomal recessive disease characterized by male pseudohermaphroditism. In LCH the testes are small with marked immaturity of the Leydig cells which correlates with undetectable plasma testosterone levels and elevated gonadotropins.
SIMILARITY: Belongs to the G-protein coupled receptor 1 family. FSH/LSH/TSH subfamily [view classification].
SIMILARITY: Contains 7 LRR (leucine-rich) repeats.
WEB RESOURCE: Name=Human luteinizing hormone receptor mutation db; URL="http://www.eur.nl/fgg/endov/lhr.html";.
WEB RESOURCE: Name=GRIS; Note=Glycoprotein-hormone Receptors Information System; URL="http://gris.ulb.ac.be/";.
WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/LHRID288.html";.
WEB RESOURCE: Name=GeneReviews; URL="http://www.genetests.org/query?gene=LHCGR";.

Copyright

Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.

Cross-references

Sequence databases

EMBL

M63108; AAA59515.1; -; mRNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
S57793; AAB19917.2; -; mRNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
M73746; AAA70231.1; -; mRNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84753; CAA59234.1; -; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84754; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84755; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84756; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84757; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84758; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84759; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84760; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84761; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84762; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
X84763; CAA59234.1; JOINED; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
AF082076; AAC98291.1; -; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
AF024642; AAB88417.1; -; Genomic_DNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]

IPI

IPI00299615; -.
IPI00414187; -.

A36243; QRHUUT.

NP_000224.2; -.

3D structure databases

PDB

1LUT; Model; -; A=51-232.	[ExPASy / RCSB / EBI]
1XUL; Model; -; C=51-232.	[ExPASy / RCSB / EBI]

Detailed list of linked structures.

PDBsum

1LUT; -.
1XUL; -.

ModBase

P22888.

Protein family/group databases

GPCRDB

P22888; LSHR_HUMAN.

PTM databases

PhosphoSite

P22888; -.

Enzyme and pathway databases

Pathway_Interaction_DB

arf6arrestinpathway; Arf6 mediated densensitization of LHCGR.
arf6cyclingpathway; Arf6 signaling events.
arf6_traffickingpathway; Arf6 trafficking events.

Organism-specific databases

GC02M048825; -.

HGNC:6585; LHCGR.

CAB009814; -.

152790; gene+phenotype. [NCBI / EBI]
176410; phenotype. [NCBI / EBI]

Orphanet

755; Leydig cell hypoplasia.
3000; Testotoxicosis.

PharmGKB

PA30357; -.

Gene expression databases

P22888; -.

P22888; -.

HS_LHCGR; -.

ENSG00000138039; Homo sapiens.

Ontologies

GO:0005768;	Cellular component: endosome (traceable author statement from ProtInc).
GO:0005887;	Cellular component: integral to plasma membrane (traceable author statement from ProtInc).
GO:0004964;	Molecular function: lutropin-choriogonadotropic hormone receptor activity (inferred from electronic annotation from InterPro).
GO:0007187;	Biological process: G-protein signaling, coupled to cyclic nucleotide second messenger (traceable author statement from ProtInc).
GO:0030539;	Biological process: male genitalia development (traceable author statement from ProtInc).
GO:0008584;	Biological process: male gonad development (traceable author statement from ProtInc).
QuickGo view.

Family and domain databases

InterPro

IPR000276; 7TM_GPCR_Rhodpsn.
IPR017452; GPCR_Rhodpsn_supfam.
IPR002131; Gphrmn_rcpt.
IPR000372; Leu-rich_rpt_Cys-rich-reg_N.
IPR002273; LSH_rcpt.
Graphical view of domain structure.

Pfam

PF00001; 7tm_1; 1.
Pfam graphical view of domain structure.

PRINTS

PR00373; GLYCHORMONER.
PR00237; GPCRRHODOPSN.
PR01144; LSHRECEPTOR.

SMART

SM00013; LRRNT; 1.
SMART graphical view of domain structure.

PROSITE

PS00237; G_PROTEIN_RECEP_F1_1; 1.
PS50262; G_PROTEIN_RECEP_F1_2; 1.
PROSITE graphical view of domain structure (profiles).

Proteomic databases

PRIDE

P22888; -.

Genome annotation databases

Ensembl

ENSG00000138039; Homo sapiens. [Contig view]

GeneID

3973; -.

KEGG

hsa:3973; -.

Phylogenomic databases

HOGENOM

P22888; -.

HOVERGEN

P22888; -.

Other

DrugBank

DB00050; Cetrorelix.
DB00097; Choriogonadotropin alfa.
DB00014; Goserelin.
DB00044; Lutropin alfa.
DB00032; Menotropins.

LHCGR; Homo sapiens.

View cluster of proteins with at least 50% / 90% / 100% identity.

Keywords

3D-structure; Alternative splicing; Cell membrane; Disease mutation; Disulfide bond; G-protein coupled receptor; Glycoprotein; Leucine-rich repeat; Lipoprotein; Membrane; Palmitate; Phosphoprotein; Polymorphism; Receptor; Repeat; Signal; Transducer; Transmembrane.

Features

Feature table viewer

Feature aligner

`Key`	`From To`	`Length`	`Description`	`FTId`
`SIGNAL`	`1 26`	`26`	`Potential.`
`CHAIN`	`27 699`	`673`	`Lutropin-choriogonadotropic hormone receptor.`	`PRO_0000012780`
`TOPO_DOM`	`27 363`	`337`	`Extracellular (Potential).`
`TRANSMEM`	`364 385`	`22`	`1 (Potential).`
`TOPO_DOM`	`386 395`	`10`	`Cytoplasmic (Potential).`
`TRANSMEM`	`396 416`	`21`	`2 (Potential).`
`TOPO_DOM`	`417 439`	`23`	`Extracellular (Potential).`
`TRANSMEM`	`440 462`	`23`	`3 (Potential).`
`TOPO_DOM`	`463 482`	`20`	`Cytoplasmic (Potential).`
`TRANSMEM`	`483 505`	`23`	`4 (Potential).`
`TOPO_DOM`	`506 525`	`20`	`Extracellular (Potential).`
`TRANSMEM`	`526 549`	`24`	`5 (Potential).`
`TOPO_DOM`	`550 570`	`21`	`Cytoplasmic (Potential).`
`TRANSMEM`	`571 594`	`24`	`6 (Potential).`
`TOPO_DOM`	`595 605`	`11`	`Extracellular (Potential).`
`TRANSMEM`	`606 627`	`22`	`7 (Potential).`
`TOPO_DOM`	`628 699`	`72`	`Cytoplasmic (Potential).`
`REPEAT`	`48 71`	`24`	`LRR 1.`
`REPEAT`	`97 121`	`25`	`LRR 2.`
`REPEAT`	`122 147`	`26`	`LRR 3.`
`REPEAT`	`149 171`	`23`	`LRR 4.`
`REPEAT`	`172 196`	`25`	`LRR 5.`
`REPEAT`	`197 220`	`24`	`LRR 6.`
`REPEAT`	`221 244`	`24`	`LRR 7.`
`LIPID`	`643 643`		`S-palmitoyl cysteine.`
`LIPID`	`644 644`		`S-palmitoyl cysteine.`
`CARBOHYD`	`99 99`		`N-linked (GlcNAc...) (Potential).`
`CARBOHYD`	`174 174`		`N-linked (GlcNAc...) (Potential).`
`CARBOHYD`	`195 195`		`N-linked (GlcNAc...) (Potential).`
`CARBOHYD`	`291 291`		`N-linked (GlcNAc...) (Potential).`
`CARBOHYD`	`299 299`		`N-linked (GlcNAc...) (Potential).`
`CARBOHYD`	`313 313`		`N-linked (GlcNAc...) (Potential).`
`DISULFID`	`439 514`		`By similarity.`
`VAR_SEQ`	`227 289`		`Missing (in isoform Short).`	`VSP_001962`
`VARIANT`	`18 18`	`1`	`Q -> QLQ.`	`VAR_003549`
`VARIANT`	`131 131`	`1`	`C -> R (in LCH).`	`VAR_010154`
`VARIANT`	`284 284`	`1`	`N -> S.`	`VAR_003550`
`VARIANT`	`291 291`	`1`	`N -> S (in dbSNP:rs12470652 [NCBI]).`	`VAR_055922`
`VARIANT`	`306 306`	`1`	`S -> N.`	`VAR_003551`
`VARIANT`	`343 343`	`1`	`C -> S (in LCH).`	`VAR_010155`
`VARIANT`	`354 354`	`1`	`E -> K (in LCH).`	`VAR_003552`
`VARIANT`	`373 373`	`1`	`A -> V (in FMPP).`	`VAR_003553`
`VARIANT`	`398 398`	`1`	`M -> T (in FMPP).`	`VAR_003554`
`VARIANT`	`457 457`	`1`	`L -> R (in FMPP).`	`VAR_010156`
`VARIANT`	`542 542`	`1`	`I -> L (in FMPP).`	`VAR_010157`
`VARIANT`	`543 543`	`1`	`C -> R (in FMPP).`	`VAR_010158`
`VARIANT`	`564 564`	`1`	`D -> G (in FMPP).`	`VAR_010159`
`VARIANT`	`564 564`	`1`	`D -> N (in a breast cancer sample; somatic mutation).`	`VAR_035764`
`VARIANT`	`568 568`	`1`	`A -> V (in FMPP).`	`VAR_003555`
`VARIANT`	`571 571`	`1`	`M -> I (in FMPP).`	`VAR_003556`
`VARIANT`	`572 572`	`1`	`A -> V (in FMPP).`	`VAR_003557`
`VARIANT`	`575 575`	`1`	`I -> L (in FMPP).`	`VAR_010160`
`VARIANT`	`577 577`	`1`	`T -> I (in FMPP).`	`VAR_003558`
`VARIANT`	`578 578`	`1`	`D -> E (in FMPP).`	`VAR_010161`
`VARIANT`	`578 578`	`1`	`D -> G (in FMPP).`	`VAR_003559`
`VARIANT`	`578 578`	`1`	`D -> H (in Leydig cell tumor; somatic mutation; causes receptor activation and precocious puberty).`	`VAR_010162`
`VARIANT`	`578 578`	`1`	`D -> Y (in FMPP).`	`VAR_010163`
`VARIANT`	`581 581`	`1`	`C -> R (in FMPP).`	`VAR_010164`
`VARIANT`	`593 593`	`1`	`A -> P (in LCH; abolishes signal transduction).`	`VAR_003560`
`VARIANT`	`608 609`	`2`	`Missing (in LCH).`	`VAR_003561`
`VARIANT`	`616 616`	`1`	`S -> Y (in LCH; micropenis).`	`VAR_003562`
`VARIANT`	`625 625`	`1`	`I -> K (in LCH).`	`VAR_003563`
`MUTAGEN`	`643 643`		`C->G: Loss of palmitoylation.`
`MUTAGEN`	`644 644`		`C->G: Loss of palmitoylation.`
`CONFLICT`	`7 7`		`A -> P (in Ref. 3; AAA70231).`
`CONFLICT`	`19 19`		`P -> A (in Ref. 3; AAA70231).`
`CONFLICT`	`27 28`		`EA -> R (in Ref. 3; AAA70231).`
`CONFLICT`	`44 51`		`CPGPTAGL -> APAPRPS (in Ref. 3; AAA70231).`
`CONFLICT`	`68 68`		`A -> S (in Ref. 3; AAA70231).`
`CONFLICT`	`124 124`		`R -> G (in Ref. 1 and 4).`
`CONFLICT`	`262 263`		`RE -> KQ (in Ref. 3; AAA70231).`
`CONFLICT`	`270 270`		`E -> R (in Ref. 3; AAA70231).`
`CONFLICT`	`274 274`		`T -> H (in Ref. 3; AAA70231).`
`CONFLICT`	`290 290`		`Q -> L (in Ref. 3; AAA70231).`
`CONFLICT`	`311 323`		`Missing (in Ref. 3; AAA70231).`
`CONFLICT`	`312 312`		`S -> N (in Ref. 2; AAB19917).`
`CONFLICT`	`448 448`		`F -> L (in Ref. 3; AAA70231).`
`CONFLICT`	`540 540`		`F -> L (in Ref. 3; AAA70231).`
`CONFLICT`	`546 546`		`Y -> T (in Ref. 2).`
`CONFLICT`	`649 649`		`E -> DP (in Ref. 3; AAA70231).`
`STRAND`	`53 55`	`3`
`TURN`	`64 66`	`3`
`HELIX`	`67 69`	`3`
`STRAND`	`77 79`	`3`
`STRAND`	`87 89`	`3`
`TURN`	`94 96`	`3`
`STRAND`	`102 104`	`3`
`TURN`	`111 113`	`3`
`HELIX`	`117 119`	`3`
`STRAND`	`127 129`	`3`
`HELIX`	`138 141`	`4`
`HELIX`	`142 145`	`4`
`STRAND`	`146 149`	`4`
`STRAND`	`152 154`	`3`
`TURN`	`159 163`	`5`
`TURN`	`167 170`	`4`
`STRAND`	`178 180`	`3`
`TURN`	`189 195`	`7`
`STRAND`	`200 203`	`4`
`TURN`	`208 212`	`5`
`HELIX`	`216 218`	`3`
`STRAND`	`226 228`	`3`

Sequence information

Length: 699 AA [This is the length of the unprocessed precursor]

Molecular weight: 78616 Da [This is the MW of the unprocessed precursor]

CRC64: 16F9980BB0ED7146 [This is a checksum on the sequence]

        10         20         30         40         50         60 
MKQRFSALQL LKLLLLLQPP LPRALREALC PEPCNCVPDG ALRCPGPTAG LTRLSLAYLP 

        70         80         90        100        110        120 
VKVIPSQAFR GLNEVIKIEI SQIDSLERIE ANAFDNLLNL SEILIQNTKN LRYIEPGAFI 

       130        140        150        160        170        180 
NLPRLKYLSI CNTGIRKFPD VTKVFSSESN FILEICDNLH ITTIPGNAFQ GMNNESVTLK 

       190        200        210        220        230        240 
LYGNGFEEVQ SHAFNGTTLT SLELKENVHL EKMHNGAFRG ATGPKTLDIS STKLQALPSY 

       250        260        270        280        290        300 
GLESIQRLIA TSSYSLKKLP SRETFVNLLE ATLTYPSHCC AFRNLPTKEQ NFSHSISENF 

       310        320        330        340        350        360 
SKQCESTVRK VSNKTLYSSM LAESELSGWD YEYGFCLPKT PRCAPEPDAF NPCEDIMGYD 

       370        380        390        400        410        420 
FLRVLIWLIN ILAIMGNMTV LFVLLTSRYK LTVPRFLMCN LSFADFCMGL YLLLIASVDS 

       430        440        450        460        470        480 
QTKGQYYNHA IDWQTGSGCS TAGFFTVFAS ELSVYTLTVI TLERWHTITY AIHLDQKLRL 

       490        500        510        520        530        540 
RHAILIMLGG WLFSSLIAML PLVGVSNYMK VSICFPMDVE TTLSQVYILT ILILNVVAFF 

       550        560        570        580        590        600 
IICACYIKIY FAVRNPELMA TNKDTKIAKK MAILIFTDFT CMAPISFFAI SAAFKVPLIT 

       610        620        630        640        650        660 
VTNSKVLLVL FYPINSCANP FLYAIFTKTF QRDFFLLLSK FGCCKRRAEL YRRKDFSAYT 

       670        680        690 
SNCKNGFTGS NKPSQSTLKL STLHCQGTAL LDKTRYTEC

P22888 in FASTA format

View entry in raw text format (no links)
Report form for errors/updates in this UniProtKB/Swiss-Prot entry

	BLAST submission on ExPASy/SIB or at NCBI (USA)		Sequence analysis tools: ProtParam, ProtScale, Compute pI/Mw, PeptideMass, PeptideCutter, Dotlet (Java)
	ScanProsite, MotifScan		Submit a homology modeling request to SWISS-MODEL
	NPSA Sequence analysis tools